Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

被引：30
作者：
Seyedmousavi, Seyedmojtaba [1 ,2 ]
Verweij, Paul E. [2 ]
Mouton, Johan W. [1 ,2 ]
机构：
[1] Erasmus MC, Dept Med Microbiol & Infect Dis, NL-3000 CA Rotterdam, Netherlands
[2] Radboudumc, Dept Med Microbiol, Nijmegen, Netherlands
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 01期
关键词：
isavuconazole; pharmacodynamics; pharmacokinetics; systemic fungal infections; IN-VITRO ACTIVITY; PHARMACODYNAMIC TARGET DETERMINATION; WATER-SOLUBLE PRODRUG; 8 ANTIFUNGAL DRUGS; CRYPTOCOCCUS-GATTII; ASPERGILLUS-FUMIGATUS; DOSE PHARMACOKINETICS; FUNGICIDAL ACTIVITIES; EUROPEAN COMMITTEE; AZOLE ANTIFUNGALS;
D O I：
10.1586/14787210.2015.990382
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
The prodrug isavuconazonium sulfate (BAL8557) is an extended-spectrum water-soluble triazole, developed for the treatment of severe invasive and life-threatening fungal diseases. Its active moiety, BAL4815, is a potent inhibitor of ergosterol biosynthesis, resulting in the disruption of fungal membrane structure and function. The active compound shows broad-spectrum of activity and potency against all major opportunistic fungi, such as Aspergillus spp., Candida spp., Cryptococcus spp., Mucorales, Black yeasts and their filamentous relatives and the true pathogenic fungi, including Histoplasma capsulatum and Blastomyces dermatitidis. It is currently in Phase III clinical development for treatment of aspergillosis, candidiasis and mucormycosis, as well as other rare fungi infections. We reviewed the pharmacokinetic and pharmacodynamic characteristics of isavuconazole, and its microbiological and clinical investigation progress in advanced stages of development.
引用
收藏
页码：9 / 27
页数：19
相关论文
共 117 条
[61]  
MATSUMOTO T, 1994, J MED VET MYCOL, V32, P329
[62]  
Meis JF, 2012, 52 INT C ANT AG CHEM
[63]   Emerging opportunistic yeast infections [J].
Miceli, Marisa H. ;
Diaz, Jose A. ;
Lee, Samuel A. .
LANCET INFECTIOUS DISEASES, 2011, 11 (02) :142-151
[64]   In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans [J].
Miller, JL ;
Schell, WA ;
Wills, EA ;
Toffaletti, DL ;
Boyce, M ;
Benjamin, DK ;
Bartroli, J ;
Perfect, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :384-387
[65]   Current options in antifungal pharmacotherapy [J].
Mohr, John ;
Johnson, Melissa ;
Cooper, Travis ;
Lewis, James S. ;
Ostrosky-Zeichner, Luis .
PHARMACOTHERAPY, 2008, 28 (05) :614-645
[66]   In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B [J].
Moore, CB ;
Walls, CM ;
Denning, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :441-443
[67]  
Moradi PW, 2013, 53 INT C ANT AG CHEM
[68]   In Vitro Activities of Eight Antifungal Drugs against 106 Waterborne and Cutaneous Exophiala Species [J].
Najafzadeh, M. J. ;
Keisari, M. Saradeghi ;
Vicente, V. A. ;
Feng, P. ;
Shamsian, S. A. A. ;
Rezaei-Matehkolaei, A. ;
de Hoog, G. S. ;
Curfs-Breuker, I. ;
Meis, J. F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) :6395-6398
[69]   In Vitro Activities of Eight Antifungal Drugs against 104 Environmental and Clinical Isolates of Aureobasidium pullulans [J].
Najafzadeh, M. Javad ;
Sutton, Deanna A. ;
Keisari, M. Saradeghi ;
Zarrinfar, H. ;
de Hoog, G. Sybren ;
Chowdhary, Anuradha ;
Meis, Jacques F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (09) :5629-5631
[70]  
Odds FC, 2006, CURR OPIN INVESTIG D, V7, P766
234567891011